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Abstract  
While SARS-CoV-2 serologic testing is used to measure cumulative incidence of COVID-19, 
appropriate signal-to-cut off (S/Co) thresholds remain unclear. We demonstrate S/Co thresholds 
based on known negative samples significantly increases seropositivity and more accurately 
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Introduction 
Designing an appropriate public health response to the pandemic requires an accurate 
estimate of the cumulative incidence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection. While serologic tests for antibodies against SARS-CoV-2 have served as the 
primary method for modeling the cumulative incidence of disease, factors including test kit 
sensitivity, waning antibody levels, and disease severity can influence seropositivity estimates 
(1-3). Another important consideration when determining serostatus is the signal-to-cut off 
(S/Co) threshold used in antibody assays to define seropositive cases. For many commonly used 
platforms, manufacturer recommended S/Co thresholds were established by testing hospitalized 
COVID-19 patients, or those with severe illness. Although these thresholds have performed well 
in populations of similar disease severity, their performance when applied to the general 
population of those infected with SARS-CoV-2 remains unclear. 
We conducted serologic testing to assess the prevalence of SARS-CoV-2-specific 
antibodies in a cohort of firefighters with a known infection history. We compared the 
performance sensitivity and specificity of manufacturer recommended S/Co values with 
modified S/Co values as determined by testing known pre-pandemic negative control samples. 
We hypothesized that alternate S/Co thresholds would improve performance characteristics and 
more accurately estimate cumulative incidence of disease in this cohort of firefighters with mild 
sickness representative of the majority of SARS-CoV-2 infected individuals. 
 
Methods 
The Los Angeles County Department of Public Health Institutional Review Board 
approved this study. We obtained written informed consent from all study participants. We 
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collected data on participant demographics and polymerase chain reaction (PCR)-confirmed 
SARS-CoV-2 infection history through electronic surveys.  
We collected EDTA plasma venipuncture samples from participants who did not report 
symptoms on the sample collection day. Serology testing was conducted at Cedars-Sinai Medical 
Center’s CLIA-certified laboratory with FDA EUA approvals, using the Abbott Architect SARS-
CoV-2 assays for IgM and IgG antibodies against spike and nucleocapsid proteins (Abbott 
Laboratories, Chicago, IL). We classified participants as being seropositive based on two 
different thresholds: the manufacturer’s recommended S/Co threshold (≥1.4 for IgG; ≥1.0 for 
IgM) and lower S/Co thresholds based on a validation study that measured antibody levels in 178 
negative control patients who had blood drawn prior to the emergence of COVID-19. We 
summarized descriptive statistics for the study and negative control cohort. We calculated the 
sensitivity and specificity for manufacturer and modified S/Co thresholds and used percent 
correctly classified to identify the optimal S/Co threshold based on these samples.   
 
Results 
Overall, 585 firefighters that received an antibody test and had a previous PCR test for 
SARS-CoV-2. Of these, 52 (8.9%) reported having a PCR-positive test history at a median 3.3 
months (Interquartile range [IQR], 1.2-4.2 months) prior to antibody testing. Table 1 presents 
demographic characteristics for individuals with a known history of infection. Most firefighters 
were male (90.4%) and between 31-59 years of age (88.5%). The most commonly identified 
racial/ethnic categories in this cohort included White (48.1%) followed by Hispanic (26.9%), 
Asian (11.5%), Black or African American (7.7%), and Other (5.8%). There were no firefighters 
that reported being previously hospitalized for the treatment of COVID-19, indicating that this 
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cohort primarily exhibited mild illness following SARS-CoV-2 infection. For the negative 
control sample, we measured SARS-CoV-2 antibodies in blood specimens drawn from 178 
individuals prior to the emergence of COVID-19. Most individuals in the negative control 
sample were male (56.2%), white (71.3%), and over 60 years of age (70.2%). The most 
commonly associated comorbidities described in this cohort included solid tumor cancer 
(69.1%), hypertension (57.9%), metastatic cancer (32.0%), hypothyroidism (30.3%), and cardiac 
arrhythmias (28.1%).  
Thirty-seven (71.2%) firefighters with a previous PCR-positive test were found to be 
seropositive for SARS-CoV-2 IgG and/or IgM antibodies based on the manufacturer 
recommended S/Co thresholds. This corresponded to a sensitivity of 71.2% (95% confidence 
interval [CI], 56.9-82.9%) and specificity of 100%. We then tested the performance of several 
modified S/Co thresholds (1.0, 0.60, 0.36, 0.34, 0.30, 0.26, 0.18), based on the index titer values 
measured in the negative control sample (Figure 1). As expected, we observed a general 
improvement in test sensitivity with lowering S/Co thresholds at the expense of declining 
specificity (Table 2). We found that a modified S/Co of 0.36 yields optimal sensitivity and 
specificity performance (percent correctly classified=97.0%) in this cohort (Table 2). When 
applying this modified threshold to estimate overall serostatus in firefighters, 47 (90.4%) 
individuals with a previous PCR-positive test result were determined to be seropositive.  
 
Discussion 
Serologic tests can be used to identify active and resolved SARS-CoV-2 infections, 
which is critical for the epidemiological tracking of COVID-19 in the population. Manufacturer 
recommended S/Co thresholds for serologic tests are typically based on samples collected from 
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symptomatic patients within a few weeks of infection. While these cut-offs have been shown to 
perform well in cohorts of similar disease severity, it has been suggested that these thresholds 
may underestimate cumulative incidence when applied to individuals with milder disease 
severity or as antibodies wane overtime (2, 3). Previous analysis of the same Abbott Architect 
instrument utilized in this study shows that manufacturer based S/Co thresholds were highly 
sensitive when applied to samples collected from hospitalized patients assayed within 17 days of 
PCR positivity (4). However, owing to the highly selective characteristics of the sensitivity 
cohort evaluated in their study, the authors speculate that modified S/Co thresholds may be 
considered for diagnostic serology in different target populations (4). 
To this end, we evaluated the performance of the Abbott Architect using manufacturer 
recommended S/Co thresholds in a cohort of firefighters with a known history of SARS-CoV-2 
infection. In contrast to previous studies evaluating the performance characteristics of this 
instrument, none of the firefighters included in the present analysis were hospitalized for the 
treatment of COVID-19. Our data demonstrate that the sensitivity of manufacturer S/Co 
thresholds significantly underperforms in ambulatory patients, particularly with increasing time 
since initial PCR positive test. As a result, we pursued alternate S/Co thresholds based on IgG-
antibody titer index values measured in known negative samples collected from pre-COVID-19 
serum.  Analysis of the percent correctly classified according to multiple alternate S/Co 
thresholds determined the optimal S/Co threshold to be 0.36. The sensitivity and specificity of 
this threshold was 90.4% (95% CI, 79.0-96.8%) and 99.4% (95% CI, 96.9-99.9%), respectively. 
When applied to the firefighter cohort, this threshold improved the overall seroprevalence 
estimate by 19.2% compared to the manufacturer recommended S/Co threshold. Given that 
approximately 85% of individuals infected by SARS-CoV-2 are not expected to be hospitalized 
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for the management of their disease, our data suggest that lowering S/Co thresholds from 
manufacturer recommended levels may be more optimal for antibody assessments in the general 
population (5).  
Overall, our data demonstrate that the use of a modified S/Co based on known negative 
samples significantly increases the percent seropositive and more accurately estimates 
cumulative incidence of infection in a cohort with a disease severity largely representative of the 
general COVID-19 population. These results are consistent with evidence from studies from US 
and Belgium which find detectable antibodies several months after infection (6, 7). In summary, 
our findings suggest that estimation of cumulative incidence of COVID-19 using serology-based 
assays must apply diagnostic thresholds that account for weaker antibody response exhibited by 
those with mild disease.  
The findings of this study should be viewed in light of its limitations. First, 
seroprevalence was assessed based on blood specimens drawn at a single, cross-sectional time 
point, resulting in varying times since initial PCR positivity. Future serology studies evaluating 
S/Co thresholds may benefit from repeated measurements to longitudinally track antibody 
kinetics over time. In addition, PCR positivity was determined by participant survey, thus we 
cannot rule out false-positive PCR test histories. Finally, it is unclear whether factors such as 
age, race/ethnicity, concomitant comorbidities, and cross-reactivity with other known 
coronaviruses influenced SARS-CoV-2 antibody measurements in the negative control cohort 
utilized in this study. Additional studies evaluating SARS-CoV-2 antibody levels in larger and 
more representative negative control specimens are needed. 
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Table 1. Characteristics of firefighter study participants and negative control cohort. 








(n=178) % P-value 
Sex 
  
   
 
Male 47 90.4% 100 56.2 <0.001 
 
Female 5 9.6% 78 43.8  
Age, y 
  
   
 
<30 5 9.6% 0 0.0% <0.001 
 
31-44 25 48.1% 16 9.0%  
 
45-59 21 40.4% 33 18.5%  
 
≥60 1 1.9% 125 70.2%  
Race/ethnicity 
  
   
 
Hispanic 14 26.9% 14 7.9% 0.003 
 
White 25 48.1% 127 71.3%  
 
Black 4 7.7% 19 10.7%  
 
Asian 6 11.5% 19 10.7%  
 
Other 3 5.8% 10 5.6%  
Previous hospitalization for COVID-19 0 0% 0 0%  
Months between PCR and antibody tests, median (IQR) 3.3 1.2-4.2 - -  
Seropositivity (manufacturer threshold ≥ 1.4) 37 71.2% - -  
 
IgM only 2 3.8% - -  
 
IgG only 12 23.1% - -  
 
IgM + IgG 23 44.2% - -  
Seropositivity (modified S/Co threshold ≥ 0.36) 47 90.4% - -  
 IgM only 1 1.9% - -  
 IgG only 14 26.9% - -  
 IgM + IgG 32 61.5% - -  
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Table 2. Analysis to determine optimal S/Co threshold. 
S/Co threshold 
Specificity (based on 
negative sample) 




1.4 100% 71.2% (56.9-82.9%) 92.6% 
1.0 99.4% (96.9-99.9%) 75.0% (61.1-86.0%) 93.5% 
0.60 99.4% (96.9-99.9%) 76.9% (63.2-87.5%) 93.9% 
0.36 99.4% (96.9-99.9%) 90.4% (79.0-96.8%) 97.0% 
0.34 98.3% (95.2-99.7%) 90.4% (79.0-96.8%) 96.1% 
0.30 97.8% (94.4-99.4%) 90.4% (79.0-96.8%) 95.7% 
0.26 97.2% (93.6-99.1%) 90.4% (79.0-96.8%) 95.2% 
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Figure 1. Index values of SARS-CoV-2 antibody titers measured in (A) serum collected from 
firefighters shown by days since PCR test positivity and (B) negative control serum collected 
from hospitalized individuals prior to COVID-19. The gray line denotes the manufacturer 
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